Clinical trial

#Calliditas Therapeutics #Cancer #Clinical trial #Head and neck cancer #Squamous cell carcinoma

Supportive interim data from Phase II head and neck cancer trial 

Calliditas Therapeutics has announced interim data from a proof-of-concept Phase II trial in patients with squamous cell carcinoma of the head and neck (SCCHN) with its lead NOX 1 and 4 inhibitor product candidate, setanaxib.    The analysis reflects encouraging early clinical progression-free survival (PFS) results and… Read More

#News

Woman using mobile phone
#Citius Pharmaceuticals #Clinical trial #Patient centricity #Patient reported outcome

Patients report improvement in haemorrhoid treatment trial

Citius Pharmaceuticals has revealed positive results from its Phase IIb Study of Halo-Lido (CITI-002) for the treatment of haemorrhoids. The high dose formulation of CITI-002, a lidocaine and halobetasol combination formulation, provided a meaningful reduction in symptom severity, as reported by patients, when compared to individual… Read More

#News

Bladder
#ASCO #Cancer research #Clinical trial #Oncology #RemeGen

Promising results for disitamab vedotin in bladder cancer

RemeGen announced the latest clinical research results on disitamab vedotin (RC48) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers tested disitamab vedotin and toripalimab in combination on patients diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC). The objective of the study… Read More

#Cancer Research #News

Respiratory system
#AnaMar #Clinical trial #Fibrosis #Lung disease #Phase I trial

Positive Phase I data for oral fibrosis treatment

AnaMar has announced positive results from its Phase I study, and the completion of Phase II enabling pre-clinical studies, for AM1476’s initial orphan indication in systemic sclerosis (SSc) characterised by lung and skin fibrosis. AM1476, a highly selective small molecule, delivered as an orally administered tablet,… Read More

#News

#Clinical research #Clinical trial #Drug discovery #Phase I trial

New episode of DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It was recently Clinical Trials Day and DDW have reported on the launch of a number… Read More

#News

#Clinical research #Clinical trial #Drug discovery #Phase I trial

This week in drug discovery (15-19 May)

News round-up for 15-19 May by DDW Digital Content Editor Diana Spencer. It’s Clinical Trials Day tomorrow and this week we have reported on the launch of a number of new Phase I trials. In-human studies have been initiated to test treatments for Parkinson’s disease, radioactive… Read More

#News

Radioactive containers
#Clinical trial #National Institute of Allergy and Infectious Diseases #Phase I trial #SRI International

Phase I trial launches into oral drug for radioactive contamination

A first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body has begun. The trial is testing the safety, tolerability and processing in the body of escalating doses of the investigational drug product HOPO 14-1 in healthy adults. Read More

#Editor's Choice #News

Esther Sammler
#Biogen #Clinical trial #Denali Therapeutics #Neurodegenerative disorders #Parkinson's #University of Dundee

New trial will investigate LRRK2 inhibitors for Parkinson’s

A study that could lead to the development of new treatments for Parkinson’s disease has launched at the University of Dundee, Scotland. The study is utilising LRRK2 inhibitors developed by Denali Therapeutics and Biogen. Mutations in the LRRK2 protein kinase are the most frequent cause of… Read More

#Editor's Choice #News

Two scientists working in a research laboratory
#BioGenCell #Clinical trial #Collaboration #Diabetes #Partnership #Phase II trial #University of California San Francisco

Industry-academia alliance targets chronic limb-threatening ischaemia

BioGenCell has partnered with the University of California San Francisco (UCSF) as part of the company’s Phase II clinical trials. The partnership will focus on the impact of BioGenCell’s treatment on those with chronic limb-threatening ischaemia (CLTI also known as CLI), a debilitating condition commonly associated… Read More

#News

Medical research
#Cancer research #Clinical trial #Oncology #Phase I trial #Solid tumours #Totus Medicines

First patient dosed with PI3Kα inhibitor for solid tumours

Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The Totus Accel Platform is designed to be the first biosearch technology that scans, maps, and… Read More

#Cancer Research #News

Asthma inhaler
#Asthma #AstraZeneca #Clinical trial #National Institute for Health and Care Excellence (NICE) #NHS England

Add-on treatment for severe uncontrolled asthma approved 

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s Tezspire (tezepelumab).  The drug is approved for use within NHS England and NHS Wales and as add-on maintenance therapy in adult and adolescent patients, 12 years and older, with severe asthma… Read More

#News

#Cancer research #Clinical research #Clinical trial #Drug discovery #Oncology #Phase I trial #Phase II trial

Podcast shares industry highlights for 3-7 April

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The headlines this week have revealed a high level of clinical trial activity taking place… Read More

#News

Pseudomonas aeruginosa bacteria
#Bacteria #Clinical trial #Infex Therapeutics #Lung disease #Phase I trial

Encouraging results for RESP-X in ongoing Phase I clinical trial

RESP-X, Infex Therapeutics’ anti-virulence therapy to treat Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients, has shown a promising interim safety and tolerability profile in its ongoing first-in-human Phase I clinical trial. The first cohort consisted of eight healthy volunteers who received doses of… Read More

#News

#Cancer research #Clinical research #Clinical trial #Drug discovery #Oncology #Phase I trial #Phase II trial

This week in drug discovery (3-7 April)

News round-up for 3-7 April by DDW Digital Content Editor Diana Spencer.  The headlines this week have revealed a high level of clinical trial activity taking place internationally. In just the last few days, new clinical trials in colorectal cancer, osteoarthritis, and brain cancer have been launched,… Read More

#News

Cancer patient receives chemotherapy via IV
#Avacta #Cancer research #Clinical trial #Oncology #Phase I trial #Solid tumours

Avacta increases dose of AVA6000 in solid tumours study

Avacta Group has dosed its first patient in the fifth cohort of the first-in-human Phase I trial (ALS-6000-101) of AVA6000 in solid tumours. This follows the approval of an amended clinical trial protocol by the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to allow for… Read More

#Cancer Research #News

Heart
#Clinical trial #Heart failure

Phase I study observes positive results for heart failure 

Sequana Medical, a company treating fluid overload in liver disease, heart failure and cancer, has announced positive results from its Phase I single-centre, single-arm, single-dose trial (CHIHUAHUA) with its second-generation DSR product (DSR 2.0).   The purpose of the trial was to evaluate the safety and tolerability profile… Read More

#News